Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$818.93 USD

818.93
5,263,033

-10.81 (-1.30%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $816.25 -2.68 (-0.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Merck (MRK) Presents New Data from Januvia Diabetes Studies

Merck (MRK) produces new data from two studies on type II diabetes medicine Januvia (sitagliptin), which supports the drug's clinical profile.

    Lilly Wins Favorable Ruling From U.S. Court in Alimta Row

    Lilly (LLY) gets a favorable ruling from a U.S. district court in a patent related dispute against Dr. Reddy's Laboratories, concerning its key cancer drug Alimta's vitamin regimen patent.

      Merck (MRK) Stock Up So Far This Year on Keytruda Strength

      Merck's shares are up 8.4% this year driven by strong performance and positive regulatory updates related to its PD-1 inhibitor, Keytruda.

        Incyte (INCY) Announces Positive Results on Jakafi for GVHD

        Incyte (INCY) reports positive results on Jakafi from the REACH trial for the indication of acute GVHD. The company plans to file a sNDA for the drug in the third quarter.

          Novo Nordisk's (NVO) Oral Ozempic Positive in Diabetes Study

          Novo Nordisk (NVO) announces positive headline results of two phase III studies PIONEER oral formulation of Ozempic (semaglutide) as a treatment for adults with type II diabetes.

            LLY vs. NVO: Which Stock Should Value Investors Buy Now?

            LLY vs. NVO: Which Stock Is the Better Value Option?

              Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?

              Is Eli Lilly and Company (LLY) Outperforming Other Medical Stocks This Year?

                Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis

                Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis

                  Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals

                  Eli Lilly (LLY)/AstraZeneca (AZN) discontinue two late-stage studies on Alzheimer's disease candidate, lanabecestat. Merck's Keytruda gets FDA nod for two new indications.

                    Allergan (AGN) Presents Positive Data on Glaucoma Candidate

                    Allergan (AGN) posts positive top-line data from a phase III study on Bimatoprost SR, a biodegradable implant for reducing IOP in patients with open-angle glaucoma or ocular hypertension.

                      Merck's Keytruda Gets FDA Nod for 2nd Lymphoma Indication

                      Merck's (MRK) Keytruda gets FDA approval for primary mediastinal B-cell lymphoma (PMBCL) - its second label expansion approval this week.

                        J&J (JNJ) Accepts Platinum Equity's Offer for LifeScan Unit

                        Johnson & Johnson (JNJ) to sell its LifeScan diabetes device unit to Platinum Equity.

                          Lilly & AstraZeneca Scrap Studies on Alzheimer's Candidate

                          Eli Lilly (LLY) and AstraZeneca (AZN) are discontinuing two late-stage studies on their Alzheimer's disease candidate, lanabecestat.

                            Allergan's Second Anti-CGRP Drug Positive in Mid-Stage Study

                            Allergan's (AGN) anti-CGRP candidate, atogepant, successful in mid-stage study, following positive data readouts from two phase III studies on another anti-CGRP candidate, ubrogepant.

                              Kinjel Shah headshot

                              Alzheimer's Research Stumbles Again: What's the Road Ahead?

                              The discontinuation of Lilly/AstraZeneca's two late-stage studies on their Alzheimer's disease candidate, lanabecestat adds to a long list of failed treatment options for this deadly brain disease.

                                AstraZeneca's Tagrisso Wins EU Nod for First-Line Lung Cancer

                                AstraZeneca's (AZN) Tagrisso gets an EU nod for first-line treatment of advanced or metastatic non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) mutations.

                                  Abbvie/Roche's Leukemia Drugs Combination Gets FDA Approval

                                  AbbVie (ABBV) and Roche's (RHHBY) cancer drugs, Venclexta and Rituxan receive approval for combination use in second-line chronic lymphocytic leukemia.

                                    Amgen's (AMGN) Prolia Gets Label Expansion Approval in Europe

                                    Amgen (AMGN) announces approval for its regulatory application seeking label expansion for Prolia in Europe.

                                      Indrajit Bandyopadhyay headshot

                                      JAK Inhibitors' Prospects Strong: 4 Stocks Ruling the Space

                                      Given the growing interest in JAK-inhibitor based treatments, here's a look at some companies that are looking to change the ways to treat autoimmune diseases.

                                        The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie

                                        The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie

                                          Pfizer Boosts Venture Capital Efforts, Neuroscience in Focus

                                          Pfizer (PFE) to pour $600 million in its venture capital arm. About 150 million will be earmarked for companies involved in promising early-stage neuroscience research.

                                            J&J Receives Buyout Offer for Sterilization Products Unit

                                            Johnson & Johnson (JNJ) receives a binding offer worth $2.8 billion from Fortive Corporation for its sterilization products business.

                                              Abbvie's (ABBV) Upadacitinib Fifth RA Study Data Positive

                                              AbbVie (ABBV) announces positive top-line results from the fifth phase III study on its JAK inhibitor, upadacitinib in moderate-to-severe rheumatoid arthritis.

                                                Merck Presents Positive Melanoma Data on Keytruda at ASCO

                                                Merck (MRK) presents encouraging data from two pivotal advanced melanoma studies on its PD-L1 inhibitor, Keytruda.

                                                  Eli Lilly's Olumiant Gets FDA Nod for Rheumatoid Arthritis

                                                  Eli Lilly (LLY) and its partner Incyte announce approval of their arthritis drug, Olumiant, in the United States. The drug will be available at two-fifth of the price of leading RA drugs.